Sicart Associates LLC Trims Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Sicart Associates LLC lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,685 shares of the life sciences company’s stock after selling 3,177 shares during the quarter. Illumina makes up approximately 2.9% of Sicart Associates LLC’s holdings, making the stock its 11th biggest position. Sicart Associates LLC’s holdings in Illumina were worth $8,109,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. Private Trust Co. NA grew its holdings in Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in Illumina during the 3rd quarter valued at approximately $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN opened at $137.37 on Friday. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The business has a fifty day moving average of $140.24 and a 200 day moving average of $133.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the company earned $0.33 earnings per share. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a report on Monday. Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Robert W. Baird increased their target price on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.